ReviewChest2015
Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.
Review in Chest, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 92 citations in OpenAlex.
- Distribution and epidemiological characteristics of nontuberculous mycobacterium species in jianghan plain.Scientific reports · 2025Article
- Epidemiology and Drug Susceptibility of Nontuberculous Mycobacteria in the Province of Pavia (Northern Italy): An Overview.Microorganisms · 2025Article
- Article
- The Advance and Clinical Practice on Lung Disease Caused byInfection and drug resistance · 2025Article
- A practical guide to the diagnosis and management of suspected Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) in the United Kingdom.NPJ primary care respiratory medicine · 2024Article
- Olink proteomics and lipidomics analysis of serum from patients infected with non-tuberculous mycobacteria and Mycobacterium tuberculosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Prevalence and antimicrobial susceptibility pattern ofHeliyon · 2024Article
- Clinical Characteristics, Species Distribution, and Drug Resistance of Non-Tuberculous Mycobacteria Lung Disease in Qingdao, China.Infection and drug resistance · 2024Article
- Massive and Lengthy Clonal Nosocomial Expansion of Mycobacterium abscessus subsp.Microbiology spectrum · 2023Article
- Conjugation of Vancomycin with a Single Arginine Improves Efficacy against Mycobacteria by More Effective Peptidoglycan Targeting.Journal of medicinal chemistry · 2023Article
- Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review.Frontiers in immunology · 2022Review
- Article
- Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Mycobacterium Avium Complex Genitourinary Infections: Case Report and Literature Review.Infectious disease reports · 2021Article
- Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Occurrence and risk factors of nontuberculous mycobacteria in tuberculosis-suspected patients in the north of Iran.Iranian journal of microbiology · 2021Article
- Article
- Genetic Analysis of Korean Adult Patients with Nontuberculous Mycobacteria Suspected of Primary Ciliary Dyskinesia Using Whole Exome Sequencing.Yonsei medical journal · 2021Article
- Highly Discriminative Genotyping ofFrontiers in microbiology · 2021Article
- Pulmonary infection caused byERJ open research · 2021Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since pulmonary nontuberculous mycobacteria (PNTM) lung disease was last reviewed in CHEST in 2008, new information has emerged spanning multiple domains, including epidemiology, transmission and pathogenesis, clinical presentation, diagnosis, and treatment. The overall prevalence of PNTM is increasing, and in the United States, areas of highest prevalence are clustered in distinct geographic locations with common environmental and socioeconomic factors. Although the accepted paradigm for transmission continues to be inhalation from the environment, provocative reports suggest that person-to-person transmission may occur. A panoply of host factors have been investigated in an effort to elucidate why infection from this bacteria develops in ostensibly immunocompetent patients, and there has been clarification that immunocompetent patients exhibit different histopathology from immunocompromised patients with nontuberculous mycobacteria infection. It is now evident that Mycobacterium abscessus, an increasingly prevalent cause of PNTM lung disease, can be classified into three separate subspecies with differing genetic susceptibility or resistance to macrolides. Recent publications also raise the possibility of improved control of PNTM through enhanced adherence to current treatment guidelines as well as new approaches to treatment and even prevention. These and other recent developments and insights that may inform our approach to PNTM lung disease are reviewed and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.